Japanese Drug Pricing Reform / 日本药品定价改革

Japanese drug pricing reform is the pharma-policy branch in vol.120.日本医疗体系的崩溃与重生：医院、药品、医保三角困局的一种解法. The episode says Japan first used broad low-price procurement and price cuts to save insurance spending, but then faced lower drug quality, generic-drug distrust, weaker profits, and innovation decline.

The post-2003 reform, as summarized by the source, tried to stop treating all drug spending as waste. First-in-class drugs could receive higher full-cycle cost-based pricing; me-better drugs could receive added-value premiums; me-too drugs stayed closer to lower anchors. The point was to protect innovation and quality without losing the insurance-cost discipline of Japanese Universal Health Coverage / 日本全民医保.

Key Claims

• Drug cost control can backfire if it pushes prices below sustainable quality and R&D levels.
• Paying more for valuable innovation can support total system efficiency if better drugs reduce downstream treatment burden.
• Pricing reform needed industry consolidation and Generic Drug Trust Rebuilding / 仿制药再信任, not just a new reimbursement formula.

Connections

• Daiichi Sankyo / 第一三共 and Takeda Pharmaceutical / 武田制药 - Japanese pharma company examples named in the source.
• Generic Drug Trust Rebuilding / 仿制药再信任 - companion generic-drug and quality branch.
• Pharmacist As Second Doctor / 药剂师第二医生体系 - patient-facing trust and medication-management branch.
• China Biotech Asset Repricing, Multinational Pharma Patent-Cliff Anxiety, and AI Clinical Validation In Drug Discovery - adjacent pharma-industry concepts already in the wiki.